Skip to content
DataLookout
Menu

CEVOLUTIONNCT07555938

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 30 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 58 words
    • Primary completion pushed from Oct 31, 2028 to Nov 30, 2028
    • Study sites: 103 to 105
    • Secondary endpoints: 28 to 27
  2. Notable Eligibility criteria shortened, about 6 words
    • Trial sites expanded: 93 → 103 locations
    • Secondary endpoints: 27 to 28
  3. Notable Eligibility criteria expanded, about 9 words
    • Trial sites expanded: 75 → 93 locations
    • Secondary endpoints: details revised at 4 of 27 entries
  4. Minor Trial sites expanded: 40 → 75 locationsv6
  5. Minor Trial sites expanded: 15 → 40 locationsv5
  6. Minor Trial sites expanded: 7 → 15 locations
    • Start date changed from estimate of Jun 30, 2026 to Jun 23, 2026
    v4
  7. Minor Trial sites expanded: 4 → 7 locationsv3
  8. Notable Recruitment openedv2 Show 4 more changesShow less
    • Start date: May 1, 2026 to Jun 30, 2026
    • Trial sites expanded: 0 → 4 locations
    • Primary completion moved earlier from Jun 29, 2029 to Oct 31, 2028
    • Study completion pushed from Dec 31, 2032 to Jan 31, 2033
  9. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate
Timeframe: Up to 1 year after the last participant is randomized
Progression-Free Survival (PFS)
Timeframe: Up to 5 years after the last participant is randomized

Secondary (27)

Very Good Partial Response (VGPR) or Better Rate
Overall Survival (OS)
Change in Disease Symptoms as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20)
Overall Response Rate (ORR)
Complete Response (CR) Rate
Show 22 moreShow less
Time to Response (TTR)
Time to Best Response (TTBR)
Duration of Response (DOR)
Progression-Free Survival (PFS)
Progression-Free Survival 2 (PFS2)
Overall MRD-Negative Complete Response Rate
Overall MRD-Negative Rate
Sustained MRD-Negative CR Rate
Percentage of Participants With Adverse Events (AEs)
Tolerability as Assessed by the Incidence of Dose Interruptions, Dose Reductions, Dose Intensity, and Treatment Discontinuation
Number of Participants With Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Function of Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed NCI PRO-CTCAE
Change From Baseline in Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)
Change From Cycle 1 Day 8 in Treatment-Related Side Effect Bother as Assessed by the Functional Assessment of Cancer Therapy-General, General Population 5 (FACTG GP5)
Change from Baseline in the Global Health Status/Quality of Life (GHS/QoL) of the EORTC QLQ-Core 30 (C30)
Time to Confirmed Deterioration in Disease Symptoms, as Assessed by EORTC QLQ-MY20
Time to Confirmed Deterioration in GHS/QoL as Assessed by the EORTC QLQ-C30
Change From Baseline in Fatigue as Assessed by the EORTC QLQ-C30
Time to Confirmed Deterioration in Fatigue as Assessed by the EORTC QLQ-C30
Percentage of Participants Experiencing Clinically Meaningful Improvement in Disease Symptoms as Assessed by the EORTC QLQ-MY20
Percentage of Participants Experiencing Clinically Meaningful Improvement in GHS/QoL as Assessed by the EORTC QLQ-C30
Percentage of Participants Experiencing Clinically Meaningful Improvement in Fatigue as Assessed by the EORTC QLQ-C30
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline and with ADAs to Cevostamab During the Study

Arms and interventions

Cevostamab + Pomalidomide + DexamethasoneExperimental

Cevostamab will be administered intravenously on a 21-day cycle in cycle 1 and on a 28-day cycle from cycle 2 onwards. Pomalidomide will be administered orally (PO) on a 28-day cycle from cycle 2 onwards. Dexamethasone will be administered as a premedication prior to cevostamab.

Standard of Care (SOC)Active comparator

Participants will receive investigator's choice of one SOC regimen.

Drugs: Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib

Sites

105 sites in 18 countries

China 14, United States 14, Japan 13, Germany 8, France 7, Spain 7, Italy 6, Poland 6, South Korea 6, Denmark 4, Israel 4, United Kingdom 4, Czechia 3, Greece 3, Australia 2, Brazil 2, Canada 1, Puerto Rico 1